Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
Background Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laborator...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2018-12, Vol.119 (12), p.1464-1470 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1470 |
|---|---|
| container_issue | 12 |
| container_start_page | 1464 |
| container_title | British journal of cancer |
| container_volume | 119 |
| creator | García-Foncillas, Jesús Tabernero, Josep Élez, Elena Aranda, Enrique Benavides, Manuel Camps, Carlos Jantus-Lewintre, Eloisa López, Rafael Muinelo-Romay, Laura Montagut, Clara Antón, Antonio López, Guillermo Díaz-Rubio, Eduardo Rojo, Federico Vivancos, Ana |
| description | Background
Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented.
Methods
Circulating cell-free DNA from plasma was examined for
RAS
mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient.
Results
The overall percentage agreement between plasma-based and tissue-based
RAS
mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue
RAS
results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease.
Conclusions
In this first prospective real-world
RAS
mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of
RAS
mutation status to determine mCRC patient eligibility for anti-EGFR therapy. |
| doi_str_mv | 10.1038/s41416-018-0293-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6288144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2154248733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-eb787501f1885e8c5f78457fd869589af1aa4c0cbab1abc1fc5329f86e170243</originalsourceid><addsrcrecordid>eNp1kd1uFSEUhSdGY4_VB_DGkHjjDQoMDMyNybGpP0lNjfaeMMyeSsPAKTBtznP4wjI5tf4kXrHJ-vZib1bTPKfkNSWtepM55bTDhCpMWN9i8aDZUNEyTBWTD5sNIURi0jNy1DzJ-apee6Lk4-aoJbyTnNJN8-NLinkHtrgbQPPii7MQCiSUwHh8G5Mf0dfttyoVU1wMyMZ5Z5LLtRyg3AIEdB5sfHe6_YwHk2FE3l0vbkSDi7u8RyaMqLicF6il8fvsMnIBzVBMXi1tdfQx1QmMR9YEC-lp82gyPsOzu_O4uXh_enHyEZ-df_h0sj3DVrRdwTBIJQWhE1VKgLJikooLOY2q64XqzUSN4ZbYwQzUDJZOtY31k-qASsJ4e9y8PdjulmGGcd07Ga93yc0m7XU0Tv-tBPddX8Yb3TGlKF8NXt0ZpHi9QC56dtmC9yZAXLJmtJW8ox3rKvryH_QqLqn-x0oJzriSbVspeqBsDSUnmO6HoUSvietD4romrtfEtag9L_7c4r7jV8QVYAcgVylcQvr99P9dfwISZLpp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2154248733</pqid></control><display><type>article</type><title>Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer</title><source>MEDLINE</source><source>Springer Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>North East Research Libraries Nature Academic Titles</source><creator>García-Foncillas, Jesús ; Tabernero, Josep ; Élez, Elena ; Aranda, Enrique ; Benavides, Manuel ; Camps, Carlos ; Jantus-Lewintre, Eloisa ; López, Rafael ; Muinelo-Romay, Laura ; Montagut, Clara ; Antón, Antonio ; López, Guillermo ; Díaz-Rubio, Eduardo ; Rojo, Federico ; Vivancos, Ana</creator><creatorcontrib>García-Foncillas, Jesús ; Tabernero, Josep ; Élez, Elena ; Aranda, Enrique ; Benavides, Manuel ; Camps, Carlos ; Jantus-Lewintre, Eloisa ; López, Rafael ; Muinelo-Romay, Laura ; Montagut, Clara ; Antón, Antonio ; López, Guillermo ; Díaz-Rubio, Eduardo ; Rojo, Federico ; Vivancos, Ana</creatorcontrib><description>Background
Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented.
Methods
Circulating cell-free DNA from plasma was examined for
RAS
mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient.
Results
The overall percentage agreement between plasma-based and tissue-based
RAS
mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue
RAS
results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease.
Conclusions
In this first prospective real-world
RAS
mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of
RAS
mutation status to determine mCRC patient eligibility for anti-EGFR therapy.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-018-0293-5</identifier><identifier>PMID: 30467411</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cancer Research ; Cell-Free Nucleic Acids - blood ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Deoxyribonucleic acid ; DNA ; Drug Resistance ; Epidemiology ; Epidermal growth factor receptors ; ErbB Receptors - antagonists & inhibitors ; Female ; Genes, ras ; Humans ; Laboratories ; Liquid Biopsy - methods ; Lung diseases ; Male ; Metastases ; Metastasis ; Middle Aged ; Molecular Medicine ; Mutation ; Neoplasm Metastasis ; Neoplastic Cells, Circulating ; Oncology ; Prospective Studies ; Tissue analysis ; Tissues ; Tumors</subject><ispartof>British journal of cancer, 2018-12, Vol.119 (12), p.1464-1470</ispartof><rights>The Author(s) 2018</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-eb787501f1885e8c5f78457fd869589af1aa4c0cbab1abc1fc5329f86e170243</citedby><cites>FETCH-LOGICAL-c536t-eb787501f1885e8c5f78457fd869589af1aa4c0cbab1abc1fc5329f86e170243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288144/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288144/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30467411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>García-Foncillas, Jesús</creatorcontrib><creatorcontrib>Tabernero, Josep</creatorcontrib><creatorcontrib>Élez, Elena</creatorcontrib><creatorcontrib>Aranda, Enrique</creatorcontrib><creatorcontrib>Benavides, Manuel</creatorcontrib><creatorcontrib>Camps, Carlos</creatorcontrib><creatorcontrib>Jantus-Lewintre, Eloisa</creatorcontrib><creatorcontrib>López, Rafael</creatorcontrib><creatorcontrib>Muinelo-Romay, Laura</creatorcontrib><creatorcontrib>Montagut, Clara</creatorcontrib><creatorcontrib>Antón, Antonio</creatorcontrib><creatorcontrib>López, Guillermo</creatorcontrib><creatorcontrib>Díaz-Rubio, Eduardo</creatorcontrib><creatorcontrib>Rojo, Federico</creatorcontrib><creatorcontrib>Vivancos, Ana</creatorcontrib><title>Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background
Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented.
Methods
Circulating cell-free DNA from plasma was examined for
RAS
mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient.
Results
The overall percentage agreement between plasma-based and tissue-based
RAS
mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue
RAS
results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease.
Conclusions
In this first prospective real-world
RAS
mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of
RAS
mutation status to determine mCRC patient eligibility for anti-EGFR therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Cancer Research</subject><subject>Cell-Free Nucleic Acids - blood</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>Female</subject><subject>Genes, ras</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Liquid Biopsy - methods</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Mutation</subject><subject>Neoplasm Metastasis</subject><subject>Neoplastic Cells, Circulating</subject><subject>Oncology</subject><subject>Prospective Studies</subject><subject>Tissue analysis</subject><subject>Tissues</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kd1uFSEUhSdGY4_VB_DGkHjjDQoMDMyNybGpP0lNjfaeMMyeSsPAKTBtznP4wjI5tf4kXrHJ-vZib1bTPKfkNSWtepM55bTDhCpMWN9i8aDZUNEyTBWTD5sNIURi0jNy1DzJ-apee6Lk4-aoJbyTnNJN8-NLinkHtrgbQPPii7MQCiSUwHh8G5Mf0dfttyoVU1wMyMZ5Z5LLtRyg3AIEdB5sfHe6_YwHk2FE3l0vbkSDi7u8RyaMqLicF6il8fvsMnIBzVBMXi1tdfQx1QmMR9YEC-lp82gyPsOzu_O4uXh_enHyEZ-df_h0sj3DVrRdwTBIJQWhE1VKgLJikooLOY2q64XqzUSN4ZbYwQzUDJZOtY31k-qASsJ4e9y8PdjulmGGcd07Ga93yc0m7XU0Tv-tBPddX8Yb3TGlKF8NXt0ZpHi9QC56dtmC9yZAXLJmtJW8ox3rKvryH_QqLqn-x0oJzriSbVspeqBsDSUnmO6HoUSvietD4romrtfEtag9L_7c4r7jV8QVYAcgVylcQvr99P9dfwISZLpp</recordid><startdate>20181211</startdate><enddate>20181211</enddate><creator>García-Foncillas, Jesús</creator><creator>Tabernero, Josep</creator><creator>Élez, Elena</creator><creator>Aranda, Enrique</creator><creator>Benavides, Manuel</creator><creator>Camps, Carlos</creator><creator>Jantus-Lewintre, Eloisa</creator><creator>López, Rafael</creator><creator>Muinelo-Romay, Laura</creator><creator>Montagut, Clara</creator><creator>Antón, Antonio</creator><creator>López, Guillermo</creator><creator>Díaz-Rubio, Eduardo</creator><creator>Rojo, Federico</creator><creator>Vivancos, Ana</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181211</creationdate><title>Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer</title><author>García-Foncillas, Jesús ; Tabernero, Josep ; Élez, Elena ; Aranda, Enrique ; Benavides, Manuel ; Camps, Carlos ; Jantus-Lewintre, Eloisa ; López, Rafael ; Muinelo-Romay, Laura ; Montagut, Clara ; Antón, Antonio ; López, Guillermo ; Díaz-Rubio, Eduardo ; Rojo, Federico ; Vivancos, Ana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-eb787501f1885e8c5f78457fd869589af1aa4c0cbab1abc1fc5329f86e170243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Cancer Research</topic><topic>Cell-Free Nucleic Acids - blood</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>Female</topic><topic>Genes, ras</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Liquid Biopsy - methods</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Mutation</topic><topic>Neoplasm Metastasis</topic><topic>Neoplastic Cells, Circulating</topic><topic>Oncology</topic><topic>Prospective Studies</topic><topic>Tissue analysis</topic><topic>Tissues</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Foncillas, Jesús</creatorcontrib><creatorcontrib>Tabernero, Josep</creatorcontrib><creatorcontrib>Élez, Elena</creatorcontrib><creatorcontrib>Aranda, Enrique</creatorcontrib><creatorcontrib>Benavides, Manuel</creatorcontrib><creatorcontrib>Camps, Carlos</creatorcontrib><creatorcontrib>Jantus-Lewintre, Eloisa</creatorcontrib><creatorcontrib>López, Rafael</creatorcontrib><creatorcontrib>Muinelo-Romay, Laura</creatorcontrib><creatorcontrib>Montagut, Clara</creatorcontrib><creatorcontrib>Antón, Antonio</creatorcontrib><creatorcontrib>López, Guillermo</creatorcontrib><creatorcontrib>Díaz-Rubio, Eduardo</creatorcontrib><creatorcontrib>Rojo, Federico</creatorcontrib><creatorcontrib>Vivancos, Ana</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Foncillas, Jesús</au><au>Tabernero, Josep</au><au>Élez, Elena</au><au>Aranda, Enrique</au><au>Benavides, Manuel</au><au>Camps, Carlos</au><au>Jantus-Lewintre, Eloisa</au><au>López, Rafael</au><au>Muinelo-Romay, Laura</au><au>Montagut, Clara</au><au>Antón, Antonio</au><au>López, Guillermo</au><au>Díaz-Rubio, Eduardo</au><au>Rojo, Federico</au><au>Vivancos, Ana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2018-12-11</date><risdate>2018</risdate><volume>119</volume><issue>12</issue><spage>1464</spage><epage>1470</epage><pages>1464-1470</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background
Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented.
Methods
Circulating cell-free DNA from plasma was examined for
RAS
mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient.
Results
The overall percentage agreement between plasma-based and tissue-based
RAS
mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue
RAS
results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease.
Conclusions
In this first prospective real-world
RAS
mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of
RAS
mutation status to determine mCRC patient eligibility for anti-EGFR therapy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30467411</pmid><doi>10.1038/s41416-018-0293-5</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2018-12, Vol.119 (12), p.1464-1470 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6288144 |
| source | MEDLINE; Springer Journals; PubMed Central; EZB Electronic Journals Library; North East Research Libraries Nature Academic Titles |
| subjects | Adult Aged Aged, 80 and over Biomedical and Life Sciences Biomedicine Biopsy Cancer Research Cell-Free Nucleic Acids - blood Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Deoxyribonucleic acid DNA Drug Resistance Epidemiology Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors Female Genes, ras Humans Laboratories Liquid Biopsy - methods Lung diseases Male Metastases Metastasis Middle Aged Molecular Medicine Mutation Neoplasm Metastasis Neoplastic Cells, Circulating Oncology Prospective Studies Tissue analysis Tissues Tumors |
| title | Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A10%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20multicenter%20real-world%20RAS%20mutation%20comparison%20between%20OncoBEAM-based%20liquid%20biopsy%20and%20tissue%20analysis%20in%20metastatic%20colorectal%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Garc%C3%ADa-Foncillas,%20Jes%C3%BAs&rft.date=2018-12-11&rft.volume=119&rft.issue=12&rft.spage=1464&rft.epage=1470&rft.pages=1464-1470&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-018-0293-5&rft_dat=%3Cproquest_pubme%3E2154248733%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2154248733&rft_id=info:pmid/30467411&rfr_iscdi=true |